Board Meeting Outcome for Outcome of Board Meeting for considering and approving Annual Audited Financial Results for the Quarter and Financial Year ended on March 31, 2026

Revenue declinedNet loss reportedQualified audit opinionExceptional itemResults View source PDF Explain this filing

ORCHPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹717.40

prior close

₹722.45

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-0.9% vs market

Pharmaceuticals peers, median of 165sector+0.2%-0.4% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.4

10m

-0.1

15m

-0.0

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+0.7-0.9+0.2-0.4

Next day

+6.6+0.7+6.0-0.1+6.7

+11.0+0.0+10.9-0.4+11.3

+7.9-1.1+9.0-1.4+9.3

+15.2+0.0+15.2-1.3+16.5

+15.8+0.3+15.6-1.7+17.5

+18.5+1.1+17.4-0.6+19.0

15d

+44.4+4.9+39.5-0.5+44.9

+32.7+5.3+27.4+2.6+30.1

+38.0+6.9+31.1+4.0+34.0

+35.4+11.9+23.5+7.1+28.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Orchid Pharma reported a 12% revenue decline for FY2026 with standalone net sales falling to Rs. 81,133 lakhs from Rs. 92,193 lakhs in FY2025. Standalone profit after tax dropped 57.5% to Rs. 4,521 lakhs, while consolidated PAT fell 79.4% to Rs. 2,055 lakhs due to losses from associates. The auditors issued an unmodified opinion on standalone results but a qualified opinion on consolidated results because three US subsidiaries' financials were unaudited. Exceptional items of Rs. 53.92 lakhs represent reversal of excess labour code provisions. The company completed acquisitions of Allecra Therapeutics assets in Germany and France, gained full ownership of Enmetazobactam (EXBLIFEP), and set up Orchid Pharma Europe GmbH. An amalgamation with holding company Dhanuka Laboratories is pending NCLT approval.

Likely market impact

The sharp revenue and profit decline combined with a qualified audit opinion on consolidated results signals deteriorating financial health. Shareholders should monitor the pending Dhanuka Laboratories amalgamation and the company's ability to restore profitability amid challenging market conditions.